Summary

The global pediatric vascular access market is projected to reach USD 833.1 million by 2030 from USD 543.0 million in 2024, at a CAGR of 7.4% during the forecast period. The pediatric vascular access market is witnessing consistent growth due to various factors such as preterm births, advancement in catheter materials in terms of safety and comfort, and growing NICU admissions. There has also been a shift towards smart vascular access devices, particularly in North America, Europe, and the Asia Pacific, where there is an increase in hospitalizations. Overall, increased healthcare expenditure in developing markets is bringing new opportunities to market growth. https://mnmimg.marketsandmarkets.com/Images/pediatric-vascular-access-market-img-overview.webp The Peripheral Intravenous Catheters (PIVC) segment of the pediatric vascular access market, by the type of catheters, is expected to hold the highest CAGR during the forecast period. The Peripheral Intravenous Catheters (PIVC) segment within the Pediatric Vascular Access market is anticipated to exhibit the highest CAGR during the forecast period due to its critical role in facilitating safe and efficient vascular access for high-risk newborns. PIVCs are designed for short-term use, typically lasting 24?96 hours. They are preferred for administering medications, fluids, and blood products in neonatal intensive care units (NICUs), where frequent interventions are required. The Ambulatory Surgical Centers (ASCs) segment of the pediatric vascular access market, by end user, is expected to show the second-highest growth. ASCs are increasingly becoming a preferred alternative to traditional hospital settings for certain neonatal interventions due to their cost-effectiveness, convenience, and focus on patient-centered care. ASCs often specialize in procedures that require advanced vascular access devices, such as peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), and midline catheters. These devices are essential for managing conditions such as congenital anomalies, preterm complications, or post-surgical recovery in a controlled, less intensive setting. The ability to perform these procedures outside of a full-scale hospital environment reduces costs while maintaining high standards of care, making ASCs an attractive option for providers and patients. Asia Pacific is expected to grow at the highest CAGR during the forecast period in the pediatric vascular access market. The pediatric vascular access market in the Asia Pacific region is growing rapidly due to demographic, economic, and healthcare infrastructure dynamics. With a rapidly growing population and rising incidence of preterm births, particularly in China and India, the demand for specialized vascular devices tailored to neonates is surging. Governments across the region are prioritizing improvements in neonatal care, investing in advanced NICUs, and upgrading healthcare facilities to align with global standards. For instance, China’s National Health Commission has launched initiatives to enhance access to critical neonatal interventions, including vascular access technologies. Japan’s sophisticated healthcare ecosystem continues to adopt cutting-edge technologies such as AI-integrated monitoring systems and ultra-miniaturized catheters. Economic expansion in the Asia Pacific is further fueling market growth as rising disposable incomes and expanding middle-class populations increase access to premium medical solutions. South Korea and Singapore are witnessing heightened adoption of smart vascular devices, driven by a culture of technological integration in healthcare. A breakdown of the primary participants referred to for this report is provided below: ? By Company Type: Tier 1: 28%, Tier 2: 34%, and Tier 3: 38% ? By Designation: C-level: 40%, Director Level: 26%, and Others: 34% ? By Region: North America: 25%, Europe: 41%, Asia Pacific: 30%, Latin America: 3%, and Middle East & Africa: 1% Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.0 billion, Tier 2 = USD 1.0 billion to USD 10.0 billion, and Tier 3 =

ページTOPに戻る

Table of Contents

1 INTRODUCTION 18
1.1 STUDY OBJECTIVES 18
1.2 MARKET DEFINITION 18
1.3 STUDY SCOPE 19
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 19
1.3.2 INCLUSIONS AND EXCLUSIONS 19
1.3.3 YEARS CONSIDERED 20
1.4 CURRENCY CONSIDERED 21
1.5 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DATA 22
2.1.1 SECONDARY DATA 22
2.1.1.1 List of secondary sources 23
2.1.1.2 Key data from secondary sources 24
2.1.2 PRIMARY DATA 24
2.1.2.1 List of primary sources 25
2.1.2.2 Key data from primary sources 25
2.1.2.3 Breakdown of primary interviews 26
2.1.2.4 Insights from industry experts 26
2.2 MARKET SIZE ESTIMATION 27
2.3 DATA TRIANGULATION 32
2.4 RESEARCH ASSUMPTIONS 33
2.5 RESEARCH LIMITATIONS 33
2.5.1 METHODOLOGY-RELATED LIMITATIONS 33
2.5.2 SCOPE-RELATED LIMITATIONS 33
2.6 RISK ASSESSMENT 34
3 EXECUTIVE SUMMARY 35
4 PREMIUM INSIGHTS 39
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PEDIATRIC VASCULAR ACCESS MARKET 39
4.2 PEDIATRIC VASCULAR ACCESS MARKET, BY REGION 40
5 MARKET OVERVIEW 41
5.1 INTRODUCTION 41
5.2 MARKET DYNAMICS 41
5.2.1 DRIVERS 42
5.2.1.1 Rapidly growing pediatric population 42
5.2.1.2 Rise of pediatric cancer 42
5.2.1.3 Heightened use of vascular access devices in pediatric patients 42
5.2.2 RESTRAINTS 43
5.2.2.1 Costly placement and maintenance of Pediatric vascular access devices 43
5.2.3 OPPORTUNITIES 43
5.2.3.1 Technological advancements in vascular access devices 43
5.2.4 CHALLENGES 43
5.2.4.1 Shortage of skilled healthcare professionals 43
5.3 TECHNOLOGY ANALYSIS 44
5.3.1 KEY TECHNOLOGIES 44
5.3.1.1 Imaging and navigation 44
5.3.1.2 Catheter securement and stabilization 44
5.3.2 COMPLEMENTARY TECHNOLOGIES 44
5.3.2.1 Artificial intelligence and machine learning 44
5.3.3 ADJACENT TECHNOLOGIES 45
5.3.3.1 Infection control technologies 45
5.4 INDUSTRY TRENDS 45
5.4.1 MINIMALLY INVASIVE VASCULAR ACCESS PROCEDURES 45
5.4.2 INNOVATIONS IN CATHETER MATERIALS AND COATINGS 45
5.5 VALUE CHAIN ANALYSIS 46
5.6 ECOSYSTEM ANALYSIS 47
5.7 SUPPLY CHAIN ANALYSIS 47
5.8 TRADE ANALYSIS 49
5.8.1 IMPORT SCENARIO (HS CODE 901839) 49
5.8.2 EXPORT SCENARIO (HS CODE 901839) 49
5.9 PORTER’S FIVE FORCES ANALYSIS 50
5.9.1 THREAT OF NEW ENTRANTS 51
5.9.2 THREAT OF SUBSTITUTES 51
5.9.3 BARGAINING POWER OF BUYERS 52
5.9.4 BARGAINING POWER OF SUPPLIERS 52
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 52
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 52
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 52
5.10.2 BUYING CRITERIA 53
5.11 REGULATORY LANDSCAPE 54
5.11.1 REGULATORY FRAMEWORK 54
5.11.1.1 North America 54
5.11.1.1.1 US 54
5.11.1.1.2 Canada 55
5.11.1.2 Europe 55
5.11.1.3 Asia Pacific 55
5.11.1.4 Latin America 56
5.11.1.5 Middle East & Africa 56
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND
OTHER ORGANIZATIONS 56
5.12 PATENT ANALYSIS 58
5.13 PRICING ANALYSIS 60
5.13.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 60
5.13.2 AVERAGE SELLING PRICE TREND, BY REGION 61
5.14 KEY CONFERENCES AND EVENTS, 2025?2026 62
5.15 ADJACENT MARKET ANALYSIS 63
5.15.1 VASCULAR ACCESS DEVICE MARKET 63
5.16 UNMET NEEDS/END USER EXPECTATIONS 64
5.17 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 65
5.18 INVESTMENT AND FUNDING SCENARIO 65
5.19 IMPACT OF AI/GEN AI 66
5.20 US 2025 TARIFF 67
5.20.1 INTRODUCTION 67
5.20.2 KEY TARIFF RATES 68
5.20.3 PRICE IMPACT ANALYSIS 69
5.20.4 IMPACT ON COUNTRY/REGION 69
5.20.4.1 US 69
5.20.4.2 Europe 70
5.20.4.3 Asia Pacific 70
5.20.5 IMPACT ON END-USE INDUSTRY 70
6 PEDIATRIC VASCULAR ACCESS MARKET, BY TYPE 71
6.1 INTRODUCTION 72
6.2 CATHETERS 73
6.2.1 CENTRAL VENOUS CATHETERS 74
6.2.1.1 Increased prevalence of preterm births to drive market 74
6.2.2 PERIPHERAL INTRAVENOUS CATHETERS 74
6.2.2.1 Rapid adoption of minimally invasive procedures to drive market 74
6.2.3 PERIPHERALLY INSERTED CENTRAL CATHETERS 75
6.2.3.1 Need for long-term vascular access in premature neonates to drive market 75
6.2.4 MIDLINE CATHETERS 77
6.2.4.1 Advancements in catheter materials and insertion techniques to drive market 77
6.3 CATHETER SECUREMENT & STABILIZATION 77
6.3.1 IMPROVED AWARENESS ABOUT CATHETER STABILIZATION TO DRIVE MARKET 77
6.4 IMPLANTABLE PORTS 78
6.4.1 RISING INCIDENCES OF PEDIATRIC CANCER TO DRIVE MARKET 78
?
6.5 PORT NEEDLES 79
6.5.1 INCREASED USE OF IMPLANTABLE PORTS IN PEDIATRIC CARE TO DRIVE MARKET 79
6.6 INFUSION PUMPS 80
6.6.1 HEIGHTENED DEMAND FOR PRECISE DRUG DELIVERY IN PEDIATRIC CARE TO DRIVE MARKET 80
6.7 IV CONNECTORS 80
6.7.1 STRINGENT HOSPITAL PROTOCOLS TO DRIVE MARKET 80
6.8 SYRINGES & NEEDLES 81
6.8.1 NEED FOR SAFE DRUG ADMINISTRATION IN PEDIATRICS TO DRIVE MARKET 81
6.9 VASCULAR CLOSURE DEVICES 82
6.9.1 SURGE IN MINIMALLY INVASIVE PROCEDURES IN PEDIATRIC TO DRIVE MARKET 82
6.10 IV SETS & ACCESSORIES 82
6.10.1 RISE IN PEDIATRIC CONDITIONS REQUIRING INTRAVENOUS THERAPY TO DRIVE MARKET 82
6.11 ANESTHESIA INJECTION DEVICES 83
6.11.1 GROWING PEDIATRICS PROCEDURES TO DRIVE MARKET 83
6.12 GUIDANCE DEVICES 84
6.12.1 ESCALATING DEMAND FOR SAFER AND MORE EFFECTIVE VASCULAR ACCESS PROCEDURES TO DRIVE MARKET 84
6.13 CATHETER CAPS & CLOSURES 84
6.13.1 ADOPTION OF INFECTION PREVENTION PROTOCOLS BY PEDIATRIC CARE UNITS TO DRIVE MARKET 84
6.14 INTRAOSSEOUS INFUSION DEVICES 85
6.14.1 RISING PEDIATRIC EMERGENCIES AND SEPSIS CASES TO DRIVE MARKET 85
6.15 OTHER TYPES 86
7 PEDIATRIC VASCULAR ACCESS MARKET, BY APPLICATION 87
7.1 INTRODUCTION 88
7.2 FLUID & NUTRITION ADMINISTRATION 88
7.2.1 NEED FOR PRECISE, CONTINUOUS THERAPY IN PEDIATRIC POPULATION TO DRIVE MARKET 88
7.3 DRUG ADMINISTRATION 89
7.3.1 RISE IN PEDIATRIC HEALTH COMPLEXITIES TO DRIVE MARKET 89
7.4 DIAGNOSTICS & TESTING 89
7.4.1 ELEVATED DEMAND FOR EARLY DISEASE DETECTION, SEPSIS MANAGEMENT, AND MONITORING TO DRIVE MARKET 89
7.5 BLOOD TRANSFUSION 89
7.5.1 PREVALENCE OF PRETERM BIRTHS AND NEONATAL ANEMIA TO DRIVE MARKET 89
?
8 PEDIATRIC VASCULAR ACCESS MARKET, BY END USER 90
8.1 INTRODUCTION 91
8.2 HOSPITALS 91
8.2.1 GROWING NICU ADMISSIONS DUE TO PREMATURE BIRTHS AND CONGENITAL CONDITIONS TO DRIVE MARKET 91
8.3 AMBULATORY SURGICAL CENTERS & CLINICS 92
8.3.1 INCREASING PREFERENCE FOR OUTPATIENT CARE TO DRIVE MARKET 92
8.4 HOMECARE SETTINGS 92
8.4.1 EMERGING TREND OF EARLY HOSPITAL DISCHARGE TO DRIVE MARKET 92
8.5 OTHER END USERS 92
9 PEDIATRIC VASCULAR ACCESS MARKET, BY REGION 93
9.1 INTRODUCTION 94
9.2 NORTH AMERICA 95
9.2.1 MACROECONOMIC OUTLOOK 95
9.2.2 US 97
9.2.2.1 Increasing burden of pediatric cancer to drive market 97
9.2.3 CANADA 97
9.2.3.1 Rising preterm births and NICU admissions to drive market 97
9.3 EUROPE 98
9.3.1 MACROECONOMIC OUTLOOK 98
9.4 ASIA PACIFIC 99
9.4.1 MACROECONOMIC OUTLOOK 99
9.4.2 JAPAN 100
9.4.2.1 Growing focus on pediatric care to drive market 100
9.4.3 CHINA 101
9.4.3.1 Substantial investments in healthcare infrastructure to drive market 101
9.4.4 REST OF ASIA PACIFIC 101
10 COMPETITIVE LANDSCAPE 102
10.1 INTRODUCTION 102
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022?2024 102
10.3 REVENUE ANALYSIS, 2022?2024 104
10.4 MARKET SHARE ANALYSIS, 2024 104
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 106
10.5.1 STARS 106
10.5.2 EMERGING LEADERS 106
10.5.3 PERVASIVE PLAYERS 106
10.5.4 PARTICIPANTS 106
10.5.5 COMPANY FOOTPRINT 108
10.5.5.1 Company footprint 108
10.5.5.2 Region footprint 109
10.5.5.3 Type footprint 110
10.5.5.4 Application footprint 112
10.5.5.5 End user footprint 113
10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024 114
10.6.1 PROGRESSIVE COMPANIES 114
10.6.2 RESPONSIVE COMPANIES 114
10.6.3 DYNAMIC COMPANIES 114
10.6.4 STARTING BLOCKS 114
10.6.5 COMPETITIVE BENCHMARKING 116
10.6.5.1 List of start-ups/SMEs 116
10.6.5.2 Competitive benchmarking of start-ups/SMEs 116
10.7 COMPANY VALUATION AND FINANCIAL METRICS 117
10.8 BRAND/PRODUCT COMPARISON 118
10.9 COMPETITIVE SCENARIO 119
10.9.1 PRODUCT LAUNCHES & APPROVALS 119
10.9.2 DEALS 120
10.9.3 OTHER DEVELOPMENTS 121
11 COMPANY PROFILES 122
11.1 KEY PLAYERS 122
11.1.1 BECTON, DICKINSON AND COMPANY 122
11.1.1.1 Business overview 122
11.1.1.2 Products offered 123
11.1.1.3 MnM view 129
11.1.1.3.1 Key strengths 129
11.1.1.3.2 Strategic choices 129
11.1.1.3.3 Weaknesses & competitive threats 129
11.1.2 TELEFLEX INCORPORATED 130
11.1.2.1 Business overview 130
11.1.2.2 Products offered 131
11.1.2.3 Recent developments 134
11.1.2.3.1 Product launches & approvals 134
11.1.2.3.2 Deals 135
11.1.2.3.3 Other developments 135
11.1.2.4 MnM view 135
11.1.2.4.1 Key strengths 135
11.1.2.4.2 Strategic choices 135
11.1.2.4.3 Weaknesses & competitive threats 136
11.1.3 ICU MEDICAL, INC. 137
11.1.3.1 Business overview 137
11.1.3.2 Products offered 138
11.1.3.3 Recent developments 142
11.1.3.3.1 Deals 142
11.1.3.4 MnM view 142
11.1.3.4.1 Right to win 142
11.1.3.4.2 Strategic choices 142
11.1.3.4.3 Weaknesses & competitive threats 142
11.1.4 B. BRAUN SE 143
11.1.4.1 Business overview 143
11.1.4.2 Products offered 144
11.1.4.3 Recent developments 149
11.1.4.3.1 Product launches & approvals 149
11.1.4.3.2 Deals 149
11.1.4.4 MnM view 150
11.1.4.4.1 Right to win 150
11.1.4.4.2 Strategic choices 150
11.1.4.4.3 Weaknesses & competitive threats 150
11.1.5 TERUMO CORPORATION 151
11.1.5.1 Business overview 151
11.1.5.2 Products offered 152
11.1.5.3 MnM view 153
11.1.5.3.1 Right to win 153
11.1.5.3.2 Strategic choice 153
11.1.5.3.3 Weaknesses & competitive threats 153
11.1.6 MEDTRONIC 154
11.1.6.1 Business overview 154
11.1.6.2 Products offered 155
11.1.7 VYGON 156
11.1.7.1 Business overview 156
11.1.7.2 Products offered 156
11.1.8 NIPRO CORPORATION 159
11.1.8.1 Business overview 159
11.1.8.2 Products offered 161
11.1.9 ANGIODYNAMICS 162
11.1.9.1 Business overview 162
11.1.9.2 Products offered 163
11.1.9.3 Recent developments 164
11.1.9.3.1 Product launches & approvals 164
11.1.9.3.2 Deals 164
11.1.10 COOK MEDICAL 165
11.1.10.1 Business overview 165
11.1.10.2 Products offered 165
?
11.2 OTHER PLAYERS 166
11.2.1 CANADIAN HOSPITAL SPECIALTIES LIMITED 166
11.2.2 MERIT MEDICAL SYSTEMS, INC. 167
11.2.3 MEDICAL COMPONENTS, INC. 168
11.2.4 AMECATH 169
11.2.5 ARGON MEDICAL DEVICES 170
11.2.6 HEALTH LINE INTERNATIONAL CORPORATION 171
11.2.7 DELTA MED 172
11.2.8 ACCESS VASCULAR, INC. 173
11.2.9 PAKUMEDMEDICAL PRODUCTS GMBH 174
11.2.10 GUANGDONG BAIHE MEDICAL TECHNOLOGY CO., LTD. 175
11.2.11 PFM MEDICAL 176
11.2.12 POLY MEDICURE LTD 177
11.2.13 NEWTECH MEDICAL DEVICES PVT. LTD. 178
11.2.14 SHANGHAI PUYI MEDICAL INSTRUMENTS CO., LTD. 179
11.2.15 ANGIPLAST PRIVATE LIMITED 180
12 APPENDIX 181
12.1 DISCUSSION GUIDE 181
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 186
12.3 CUSTOMIZATION OPTIONS 188
12.4 RELATED REPORTS 188
12.5 AUTHOR DETAILS 189

ページTOPに戻る

List of Tables/Graphs

TABLE 1 STANDARD CURRENCY CONVERSION RATES 21
TABLE 2 IMPORT DATA FOR HS CODE 901839-COMPLIANT PRODUCTS, BY COUNTRY, 2019?2024 (USD THOUSAND) 49
TABLE 3 EXPORT DATA FOR HS CODE 901839-COMPLIANT PRODUCTS,
BY COUNTRY, 2019?2024 (USD THOUSAND) 50
TABLE 4 PORTER’S FIVE FORCES ANALYSIS 50
TABLE 5 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR
TOP THREE TYPES 53
TABLE 6 KEY BUYING CRITERIA FOR TOP THREE TYPES 53
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 56
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 57
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 57
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 58
TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 58
TABLE 12 AVERAGE SELLING PRICE TREND, BY KEY PLAYERS, 2022?2024 (USD) 60
TABLE 13 AVERAGE SELLING PRICE TREND, BY REGION, 2022?2024 (USD) 61
TABLE 14 KEY CONFERENCES AND EVENTS, 2025?2026 62
TABLE 15 UNMET NEEDS/END USER EXPECTATIONS 64
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 68
TABLE 17 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR VASCULAR ACCESS DEVICES 69
TABLE 18 PEDIATRIC VASCULAR ACCESS MARKET, BY TYPE,
2023?2030 (USD MILLION) 72
TABLE 19 PEDIATRIC VASCULAR ACCESS MARKET FOR CATHETERS,
BY REGION, 2023?2030 (THOUSAND UNITS) 73
TABLE 20 PEDIATRIC VASCULAR ACCESS MARKET FOR CATHETERS,
BY TYPE, 2023?2030 (USD MILLION) 73
TABLE 21 PEDIATRIC VASCULAR ACCESS MARKET FOR CENTRAL VENOUS CATHETERS,
BY REGION, 2023?2030 (USD MILLION) 74
TABLE 22 PEDIATRIC VASCULAR ACCESS MARKET FOR PERIPHERAL INTRAVENOUS CATHETERS, BY REGION, 2023?2030 (USD MILLION) 75
TABLE 23 PEDIATRIC VASCULAR ACCESS MARKET FOR PERIPHERALLY INSERTED CENTRAL CATHETERS, BY REGION, 2023?2030 (USD MILLION) 75
TABLE 24 PEDIATRIC VASCULAR ACCESS MARKET FOR MIDLINE CATHETERS, BY REGION, 2023?2030 (USD MILLION) 77
TABLE 25 PEDIATRIC VASCULAR ACCESS MARKET FOR CATHETER SECUREMENT & STABILIZATION, BY REGION, 2023?2030 (USD MILLION) 78
TABLE 26 PEDIATRIC VASCULAR ACCESS MARKET FOR IMPLANTABLE PORTS, BY REGION, 2023?2030 (USD MILLION) 79
TABLE 27 PEDIATRIC VASCULAR ACCESS MARKET FOR PORT NEEDLES,
BY REGION, 2023?2030 (USD MILLION) 79
TABLE 28 PEDIATRIC VASCULAR ACCESS MARKET FOR INFUSION PUMPS, BY REGION, 2023?2030 (USD MILLION) 80
TABLE 29 PEDIATRIC VASCULAR ACCESS MARKET FOR IV CONNECTORS,
BY REGION, 2023?2030 (USD MILLION) 81
TABLE 30 PEDIATRIC VASCULAR ACCESS MARKET FOR SYRINGES & NEEDLES, BY REGION, 2023?2030 (USD MILLION) 81
TABLE 31 PEDIATRIC VASCULAR ACCESS MARKET FOR VASCULAR CLOSURE DEVICES, BY REGION, 2023?2030 (USD MILLION) 82
TABLE 32 PEDIATRIC VASCULAR ACCESS MARKET FOR IV SETS & ACCESSORIES, BY REGION, 2023?2030 (USD MILLION) 83
TABLE 33 PEDIATRIC VASCULAR ACCESS MARKET FOR ANESTHESIA INJECTION DEVICES, BY REGION, 2023?2030 (USD MILLION) 83
TABLE 34 PEDIATRIC VASCULAR ACCESS MARKET FOR GUIDANCE DEVICES, BY REGION, 2023?2030 (USD MILLION) 84
TABLE 35 PEDIATRIC VASCULAR ACCESS MARKET FOR CATHETER CAPS & CLOSURES, BY REGION, 2023?2030 (USD MILLION) 84
TABLE 36 PEDIATRIC VASCULAR ACCESS MARKET FOR INTRAOSSEOUS INFUSION DEVICES, BY REGION, 2023?2030 (USD MILLION) 86
TABLE 37 PEDIATRIC VASCULAR ACCESS MARKET FOR OTHER TYPES,
BY REGION, 2023?2030 (USD MILLION) 86
TABLE 38 PEDIATRIC VASCULAR ACCESS MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 88
TABLE 39 PEDIATRIC VASCULAR ACCESS MARKET, BY END USER,
2023?2030 (USD MILLION) 91
TABLE 40 PEDIATRIC VASCULAR ACCESS MARKET, BY REGION,
2023?2030 (USD MILLION) 95
TABLE 41 NORTH AMERICA: PEDIATRIC VASCULAR ACCESS MARKET,
BY COUNTRY, 2023?2030 (USD MILLION) 96
TABLE 42 US: KEY MACRO INDICATORS 97
TABLE 43 CANADA: KEY MACRO INDICATORS 98
TABLE 44 ASIA PACIFIC: PEDIATRIC VASCULAR ACCESS MARKET,
BY COUNTRY, 2023?2030 (USD MILLION) 100
TABLE 45 JAPAN: KEY MACRO INDICATORS 100
TABLE 46 CHINA: KEY MACRO INDICATORS 101
TABLE 47 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022?2024 102
TABLE 48 PEDIATRIC VASCULAR ACCESS MARKET:
DEGREE OF COMPETITION 105
TABLE 49 REGION FOOTPRINT 109
TABLE 50 TYPE FOOTPRINT 110
TABLE 51 APPLICATION FOOTPRINT 112
TABLE 52 END USER FOOTPRINT 113
TABLE 53 LIST OF START-UPS/SMES 116
TABLE 54 COMPETITIVE BENCHMARKING OF START-UPS/SMES 116
TABLE 55 PEDIATRIC VASCULAR ACCESS MARKET: PRODUCT LAUNCHES & APPROVALS, 2022?2025 119
TABLE 56 PEDIATRIC VASCULAR ACCESS MARKET: DEALS, 2022?2025 120
TABLE 57 PEDIATRIC VASCULAR ACCESS MARKET:
OTHER DEVELOPMENTS, 2022?2025 121
TABLE 58 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 122
TABLE 59 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 123
TABLE 60 TELEFLEX INCORPORATED: COMPANY OVERVIEW 130
TABLE 61 TELEFLEX INCORPORATED: PRODUCTS OFFERED 131
TABLE 62 TELEFLEX INCORPORATED: PRODUCT LAUNCHES & APPROVALS 134
TABLE 63 TELEFLEX INCORPORATED, INC:. DEALS 135
TABLE 64 TELEFLEX INCORPORATED: OTHER DEVELOPMENTS 135
TABLE 65 ICU MEDICAL, INC.: COMPANY OVERVIEW 137
TABLE 66 ICU MEDICAL, INC.: PRODUCTS OFFERED 138
TABLE 67 ICU MEDICAL, INC.: DEALS 142
TABLE 68 B. BRAUN SE: COMPANY OVERVIEW 143
TABLE 69 B. BRAUN SE: PRODUCTS OFFERED 144
TABLE 70 B. BRAUN SE: PRODUCT LAUNCHES & APPROVALS 149
TABLE 71 B. BRAUN SE: DEALS 149
TABLE 72 TERUMO CORPORATION: COMPANY OVERVIEW 151
TABLE 73 TERUMO CORPORATION: PRODUCTS OFFERED 152
TABLE 74 MEDTRONIC: COMPANY OVERVIEW 154
TABLE 75 MEDTRONIC: PRODUCTS OFFERED 155
TABLE 76 VYGON: COMPANY OVERVIEW 156
TABLE 77 VYGON: PRODUCTS OFFERED 156
TABLE 78 NIPRO CORPORATION: COMPANY OVERVIEW 159
TABLE 79 NIPRO CORPORATION: PRODUCTS OFFERED 161
TABLE 80 ANGIODYNAMICS: COMPANY OVERVIEW 162
TABLE 81 ANGIODYNAMICS: PRODUCTS OFFERED 163
TABLE 82 ANGIODYNAMICS: PRODUCT LAUNCHES & APPROVALS 164
TABLE 83 ANGIODYNAMICS: DEALS 164
TABLE 84 COOK MEDICAL: COMPANY OVERVIEW 165
TABLE 85 COOK MEDICAL: PRODUCTS OFFERED 165FIGURE 1 PEDIATRIC VASCULAR ACCESS MARKET SEGMENTATION 19
FIGURE 2 RESEARCH DESIGN 22
FIGURE 3 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 27
FIGURE 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 28
FIGURE 5 MARKET SIZE ESTIMATION: DEMAND-SIDE ANALYSIS 29
FIGURE 6 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 30
FIGURE 7 PEDIATRIC VASCULAR ACCESS MARKET: CAGR PROJECTIONS 30
FIGURE 8 DATA TRIANGULATION 32
FIGURE 9 CATHETERS TO BE LARGEST SEGMENT DURING FORECAST PERIOD 35
FIGURE 10 FLUID & NUTRITION ADMINISTRATION SEGMENT TO SECURE LEADING POSITION DURING FORECAST PERIOD 36
FIGURE 11 HOSPITALS TO SURPASS OTHER SEGMENTS DURING FORECAST PERIOD 37
FIGURE 12 ASIA PACIFIC TO BE FASTEST-GROWING MARKET FOR VASCULAR
ACCESS DEVICES DURING FORECAST PERIOD 38
FIGURE 13 RISE OF PEDIATRIC POPULATION TO DRIVE MARKET 39
FIGURE 14 NORTH AMERICA TO BE DOMINANT DURING FORECAST PERIOD 40
FIGURE 15 PEDIATRIC VASCULAR ACCESS MARKET DYNAMICS 41
FIGURE 16 VALUE CHAIN ANALYSIS 46
FIGURE 17 ECOSYSTEM ANALYSIS 47
FIGURE 18 SUPPLY CHAIN ANALYSIS 48
FIGURE 19 PORTER’S FIVE FORCES ANALYSIS 51
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE TYPES 53
FIGURE 21 KEY BUYING CRITERIA FOR TOP THREE TYPES 53
FIGURE 22 PATENT ANALYSIS, 2014?2024 59
FIGURE 23 TOP APPLICANT REGIONS, 2014?2025 60
FIGURE 24 AVERAGE SELLING PRICE TREND OF CENTRAL VENOUS CATHETERS, BY REGION, 2022?2024 (USD) 61
FIGURE 25 VASCULAR ACCESS DEVICE MARKET OVERVIEW 63
FIGURE 26 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 65
FIGURE 27 INVESTMENT AND FUNDING SCENARIO, 2019?2023 65
FIGURE 28 IMPACT OF AI/GEN AI 67
FIGURE 29 PEDIATRIC VASCULAR ACCESS MARKET, BY REGION 94
FIGURE 30 NORTH AMERICA: PEDIATRIC VASCULAR ACCESS
DEVICE MARKET SNAPSHOT 96
FIGURE 31 ASIA PACIFIC: PEDIATRIC VASCULAR ACCESS MARKET SNAPSHOT 99
FIGURE 32 REVENUE ANALYSIS OF TOP THREE PLAYERS, 2022?2024 104
FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 104
FIGURE 34 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 107
FIGURE 35 COMPANY FOOTPRINT 108
FIGURE 36 COMPANY EVALUATION MATRIX (START-UPS/SMES), 2024 115
FIGURE 37 EV/EBITDA OF KEY VENDORS 117
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK
BETA OF KEY VENDORS 117
FIGURE 39 BRAND/PRODUCT COMPARISON 118
FIGURE 40 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 123
FIGURE 41 TELEFLEX INCORPORATED: COMPANY SNAPSHOT 131
FIGURE 42 ICU MEDICAL, INC.: COMPANY SNAPSHOT 138
FIGURE 43 B. BRAUN SE: COMPANY SNAPSHOT 144
FIGURE 44 TERUMO CORPORATION: COMPANY SNAPSHOT 152
FIGURE 45 MEDTRONIC: COMPANY SNAPSHOT 155
FIGURE 46 NIPRO CORPORATION: COMPANY SNAPSHOT 160
FIGURE 47 ANGIODYNAMICS: COMPANY SNAPSHOT 163